Interviews Archives - Page 2 of 3

Interviews

UCSF’s interview with Rob Nelson of ARCH Venture Partners

ARCH Venture Partners is behind companies such as Illumina, Alnylam, Unity Biotechnology, Receptos, Agios Pharmaceuticals, Grail, Bluebird, and many more. This interview is part of…

clement24.05.2019

Interviews

We are a small company with a big portfolio

“We are a small company with a big portfolio” After Martine and Jean-Paul Clozel created Actelion with two other founders and grew Actelion into Europe’s…

clement22.01.2019

Interviews

“We help to translate research into product, which benefits patients or society at large”

Herbert Reutimann, the CEO of Unitectra, the joint technology transfer organization of the Universities of Basel, Bern and Zurich, talks about the ways in which…

clement11.12.2018

Interviews

Investment Strategies in Biotech with Chandra Leo, HBM Partners

clement05.11.2018

Giacomo di Nepi Polyphor CEO - largest biotech IPO

Interviews

“The largest biotech IPO in Switzerland within the last ten years”

Giacomo di Nepi has a successful history: A high level executive in big corporations, he transitioned towards biotech, currently as CEO of Polyphor, which, in…

clement10.09.2018

Interviews

Selection committe member Julian Bertschinger

The competition for financing is intense. How and which projects do you choose to back? Julian Bertschinger: At Johnson & Johnson we collaborate with and…

clement10.07.2018

Roivant will not shy away from taking risks

Interviews

“We will not shy away from taking risks”

In 2016, Roivant Sciences established their global headquarters in Basel. Roivant founder and CEO Vivek Ramaswamy talked to us about his fast growing company, his priorities…

clement04.07.2018

Interviews

“Basel has all the ingredients required to host a successful company”

The physician and pharmacologist Nicole Onetto is a member of the Board of Directors at the Basilea Pharmaceutica AG. In the Interview that was featured…

clement11.06.2018

Interviews

Processes kill innovation

The serial entrepreneur Neil Goldsmith is drawn to new ventures. Annett Altvater from BaselArea.swiss talked to him about how to detect startup-suitable talent and his…

clement07.06.2018

Interviews

Biotech and Why Pharma Should Be Very Afraid

Xconomy National — Arch Venture Partners co-founder and managing director Bob Nelsen is widely regarded as one of the most astute and successful life science investors and…

clement15.05.2018

Interviews

UCSF’s interview with Rob Nelson of ARCH Venture Partners

We are a small company with a big portfolio

“We help to translate research into product, which benefits patients or society at large”

Investment Strategies in Biotech with Chandra Leo, HBM Partners

“The largest biotech IPO in Switzerland within the last ten years”

Selection committe member Julian Bertschinger

“We will not shy away from taking risks”

“Basel has all the ingredients required to host a successful company”

Processes kill innovation

Biotech and Why Pharma Should Be Very Afraid

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us